Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution
文献类型：期刊论文
| 作者 | Chen, Chong2; Liu, Kun2; Xu, Yupeng2; Zhang, Pengwei1; Suo, Yan2; Lu, Yi2; Zhang, Wenyuan3; Su, Li2; Gu, Qing2; Wang, Huamao1 |
| 刊名 | BIOMATERIALS
 |
| 出版日期 | 2017-01 |
| 卷号 | 112页码:218-233 |
| 关键词 | Angiogenesis inhibitor Cell-penetrating peptides Intraocular drug delivery In vivo-direction evolution Neovascularization Phage display |
| ISSN号 | 0142-9612 |
| DOI | 10.1016/j.biomaterials.2016.09.022 |
| 文献子类 | Article |
| 英文摘要 | Anti-vascular endothelial growth factor (VEGF) therapies are widely used for the treatment of neovascular fundus diseases such as diabetic retinopathy. However, these agents need to be injected intravitreally, because their strong hydrophilicity and high molecular weight prevent them from penetrating cell membranes and complex tissue barriers. Moreover, the repeated injections that are required can cause infection and tissue injury. In this study, we used in vivo-directed evolution phage display technology to identify a novel dodecapeptide, named CC12, with the ability to penetrate the ocular barrier in a noninvasive (via conjunctival sac instillation) or minimally invasive (via retrobulbar injection) manner. KV11, an antiangiogenesis peptide previously demonstrated to inhibit pathological neovascularization in the retina, was then used as a model antiangiogenesis cargo for CC12. We found that conjugation of KV11 peptide with CC12 peptide facilitated the delivery of KV11 to the retina, resulting in significant inhibition of retinal neovascularization development via topical application without tissue toxicity. Collectively, our data of multilevel evaluations demonstrate that CC12 may enable the noninvasive to minimally invasive intraocular delivery of antiangiogenic therapeutics. (C) 2016 Elsevier Ltd. All rights reserved. |
| WOS关键词 | CELL-PENETRATING PEPTIDES ; RETINAL-PIGMENT EPITHELIUM ; OCULAR DRUG-DELIVERY ; IN-VIVO ; INHIBITS ANGIOGENESIS ; ENDOTHELIAL-CELLS ; HEPARAN-SULFATE ; RATIONAL DESIGN ; POLYPROLINE-II ; BRAIN DELIVERY |
| 资助项目 | National Science and Technology Pillar Project[2011ZX09302-007-02] ; National Natural Science Foundation of China[81300753] ; National Natural Science Foundation of China[81273424] ; National Natural Science Foundation of China[81170862] |
| WOS研究方向 | Engineering ; Materials Science |
| 语种 | 英语 |
| WOS记录号 | WOS:000389166700019 |
| 出版者 | ELSEVIER SCI LTD |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/275755]  |
| 专题 | 中国科学院上海药物研究所 |
| 通讯作者 | Li, Zonghai; Xu, X. |
| 作者单位 | 1.Shanghai Jiao Tong Univ, Shanghai Canc Inst, Renji Hosp, State Key Lab Oncogenes & Related Genes, Shanghai 200032, Peoples R China; 2.Shanghai Jiao Tong Univ, Shanghai Key Lab Fundus Dis, Dept Ophthalmol, Shanghai Gen Hosp, Shanghai, Peoples R China; 3.Chinese Acad Sci, Shanghai Inst Mat Med, Shanghai 201203, Peoples R China |
| 推荐引用方式 GB/T 7714 | Chen, Chong,Liu, Kun,Xu, Yupeng,et al. Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution[J]. BIOMATERIALS,2017,112:218-233. |
| APA | Chen, Chong.,Liu, Kun.,Xu, Yupeng.,Zhang, Pengwei.,Suo, Yan.,...&Xu, X..(2017).Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution.BIOMATERIALS,112,218-233. |
| MLA | Chen, Chong,et al."Anti-angiogenesis through noninvasive to minimally invasive intraocular delivery of the peptide CC12 identified by in vivo-directed evolution".BIOMATERIALS 112(2017):218-233. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。